Cancer cells with BRCA1/2 mutations treated with PARP inhibitors lead to cell cycle arrest and apoptosis through synthetic lethality4,5, thus the PARP-1 protein has become an attractive target for the treatment of cancers in recent years.6 Here, BRCA1 is linked to cancer.